ASCLETIS(01672)

Search documents
异动盘点0703|港股医药再走高,信达生物涨超4%;零跑涨超3%,Adobe跌超 3%,Circle跌超 6%
贝塔投资智库· 2025-07-03 03:50
点击蓝字,关注我们 今日上午港股 1.赣锋锂业 (01772) 再涨超 3%, Mali Lithium 旗下马里 Goulamina 锂辉石项目一期已正式投产. 6.歌礼制药 - B (01672) 现涨超 6% , 消息面上,歌礼制药公布,ASC30 完成首批受试者给药 预计四季 度获得实验数据。 2.德林国际 (01126) 涨超 6% ,消息面上产能布局中国 + 越南 + 印尼 公司有望持续受益潮玩盛行趋势。 7.金山软件 (03888) 再跌近 7% , 消息面上,金山软件旗下新游《解限机》正式开启公测 市场关注新游 表现。 3.环球新材国际 (06616) 再涨超 7% , 消息面上,环球新材国际公布收购默克表面解决方案业务交易事 项即将落地。 8.国泰君安国际 (01788) 涨超 5% , 消息面上,6 月 24 日,国泰君安国际正式获香港证监会批准,将现 有证券交易牌照升级为可提供虚拟资产交易服务。 4..零跑汽车 (09863) 涨超 3% , 消息面上,7 月 1 日,零跑汽车宣布与 Stellantis 达成价值 15 亿碳积分转 让协议。 5.仔机器人 (00370) 涨超 6% , ...
速递|GLP-1药物专利战打响!石药向歌礼美国专利发起挑战
GLP1减重宝典· 2025-06-30 07:46
Core Viewpoint - The article discusses the ongoing patent dispute between Songlei and Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, regarding the validity of a US patent held by Songlei, which is currently under review by the USPTO [1][3]. Group 1: Patent Dispute Details - On June 30, Songlei announced that it was informed on June 24 about Conjupro's request for a Post Grant Review at the USPTO, questioning the validity of specific claims in Songlei's US patent (Patent No: 12,234,236) [1]. - Conjupro's application for "Compound 10" is claimed to be structurally identical to Songlei's "Compound 1," with Songlei asserting that its patent application was submitted over three months prior to Conjupro's [1]. - As of the announcement, the review request is still under examination by the USPTO [1]. Group 2: Background and Implications - Songlei noted that it could not ascertain the specific reasons behind Conjupro's review request, but highlighted that Conjupro had previously sought global licensing discussions for the GLP-1R agonist Compound 1, which Songlei declined [3]. - The patent in question is based on proprietary technology developed by Songlei and is currently being utilized in the development of the candidate drug ASC30, with multiple related molecules protected under various patent systems [4]. - The USPTO officially granted the patent rights to Songlei on February 25, 2025, citing its innovation and non-obviousness compared to existing technologies [4].
歌礼制药-B(01672)专利遭石药挑战 公司称将全力捍卫
智通财经网· 2025-06-30 00:21
该专利系利用歌礼专有技术开发而成,目前正应用于公司候选药物ASC30的研发。公司包括化合物1和 ASC30在内的化合物受多项专利保护,包括前述该专利。基于其与现有技术相比具有新颖性和非显而易 见性,USPTO已于2025年2月25日将该专利权授予公司附属公司歌礼制药(中国)有限公司。 公司对于该专利的有效性充满信心,如该复审继续推进,公司将采取一切必要的法律手段捍卫公司的知 识产权。 由于该复审目前仍在USPTO审查中,当前阶段该复审对集团无潜在影响。公司将密切关注该复审的进 展并评估其影响,与此同时,当前公司的业务及运营未受影响。 智通财经APP讯,歌礼制药-B(01672)发布公告,该公司董事会于2025年6月24日获悉由石药集团有限公 司(一家于香港联合交易所有限公司上市的公司,股份代号:1093)附属公司康久普乐生物医疗有限公司 (Conjupro Biotherapeutics, Inc.)向美国专利商标局(USPTO)提交的一项复审。该复审质疑公司附属公司歌 礼制药(中国)有限公司一项已获授权的美国专利(美国专利号:12,234,236)权利要求 1-9、12-17及21-25 的有效性。截至本公 ...
歌礼制药-B(1672.HK):创新管线登上ADA大会 公司后续发展值得期待
Ge Long Hui· 2025-06-27 00:23
Core Viewpoint - The company's ASC30 and ASC47 drugs showcased at the ADA conference have promising future prospects, with ASC30 demonstrating good pharmacokinetic characteristics and safety, while ASC47 shows potential for fat reduction and muscle gain in preclinical studies [1][2]. Event Summary - On June 18, the company announced the completion of the first dosing of subjects in the U.S. Phase I clinical trial for ASC50, an oral small molecule IL-17 inhibitor for psoriasis [1]. - On June 23, ASC30 and ASC47 were presented at the ADA conference, highlighting their clinical research data [1]. ASC30 Insights - The SAD study for ASC30 included 30 subjects divided into five groups with doses of 2mg, 5mg, 10mg, 20mg, and 40mg, showing a half-life of 30-55 hours for the 5-40mg groups, indicating favorable pharmacokinetic properties [1][2]. - The study reported that all side effects were mild to moderate, with no vomiting in the 2mg and 5mg groups, confirming the drug's controllable safety profile [2]. ASC47 Insights - Preclinical studies of ASC47 indicated its potential for fat reduction, muscle gain, and weight loss, particularly when combined with semaglutide in mouse models, showing a greater weight loss trend compared to the semaglutide-only group [2]. ASC50 Potential - ASC50 is positioned as a promising oral treatment for psoriasis, currently undergoing Phase I clinical trials in the U.S. The preclinical data suggest higher oral exposure, longer half-life, and strong efficacy, supporting its potential as a best-in-class oral medication [2]. Future Development Outlook - The company plans to continue advancing its core pipeline, with ASC30's oral Phase IIa study and ASC40's Phase III study expected to be completed by 2025, alongside the publication of ASC30's subcutaneous Phase Ib results [3]. - The focus remains on ASC30 and ASC47, with multiple pipeline developments anticipated in the coming years [3]. Financial Forecast - The core drugs ASC30 and ASC47 are in early development stages, showing excellent safety and efficacy in early clinical results. The company estimates a reasonable market value of HKD 19.29 billion, raising the target price to HKD 19.93, maintaining a "buy" rating [3].
港股异动 | 歌礼制药-B(01672)再涨超18% 地尼法司他数据亮眼 公司将公布ASC30及ASC47研究结果
智通财经网· 2025-06-16 03:31
消息面上,歌礼制药近日公布,同类首创、每日一次口服小分子脂肪酸合成酶(FASN)抑制剂地尼法司 他(ASC40)治疗中重度寻常性痤疮的III期临床试验(NCT06192264)达到所有主要、关键次要及次要终 点。东吴证券指出,目前痤疮疗法治标不治本,而地尼法司他III期临床达到所有终点,疗效数据优秀, 未来有望成为疗效显著、患者依从性高、安全性好的BIC痤疮药物。随着地尼法司他III临床期顺利结 束,公司预计将在2025年提交药监局申报上市,2026年贡献收入。 此外,歌礼制药将在美国芝加哥举行的美国糖尿病协会(ADA)第85届科学会议上,以壁报形式报告口服 小分子GLP-1受体(GLP-1R)激动剂ASC30,以及脂肪靶向、减重不减肌候选药物ASC47的早期研究数 据。东吴证券指出,ASC30是目前唯一一款既可每天口服,也可每月一次皮下注射的GLP-1小分子,满 足了不同市场人群的需求,具备稀缺性;ASC47是靶向脂肪细胞THRβ靶点的小分子药物,每月一次皮 下注射,有减脂不减肌潜力,是首个THRβ靶点的小分子减肥药。目前I期SAD研究数据已读出,在美国 联合司美格鲁肽临床研究已经完成首例患者给药。 智通财 ...
从FDA拒绝,到超500亿美元爆单全球!中国创新药十年逆袭之路
21世纪经济报道· 2025-06-12 13:30
作 者丨季媛媛 闫硕 周亦洋 编 辑丨林虹 张星 图 源丨AI 凌晨两点,波士顿海港区会议中心,落地窗外的大西洋漆黑如墨。 而就在七年前,同样在波士顿,一个深夜来电曾击碎过王黎的幻想——当中国药企兴冲冲捧着实验室成果走向世界 时,国际监管机构冰冷的质疑往往成为第一道致命冰墙。 冰封航线 2018年寒冬,彼时尚任跨国药企研发骨干的王黎接到国内一家新兴生物技术公司创始人的越洋电话。电话那头声音沙 哑:"FDA(美国食品药品监督管理局)拒绝安排会议……他们说试验设计不符合国际规范。" 这不是孤例。当中国药企怀揣创新药勇闯深海,却在三个暗礁前接连触底: 临床试验设计如同闭门造车。某明星抗癌药一期数据惊艳,却在FDA审查中漏洞百出。"不是数据本身不行",一位曾 深度参与早期项目的CRO(合同研究组织)负责人回忆,"是我们根本不懂游戏规则,不知道FDA审评员真正关心什 么、疑虑什么。" 专利布局更成致命伤。某明星抗肿瘤药物license-out谈判临门一脚时,国际大厂突然亮出杀手锏——核心化合物专利 存在地域保护漏洞,交易瞬间冻结。"从立项之初,企业是否就将全球市场作为靶点,是否建立了贯穿药物全生命周期 的全球知识产权战 ...
歌礼制药-B(01672)将在ADA第85届科学会议上以壁报形式报告口服小分子GLP-1R激动剂ASC30及脂肪靶向、减重不减肌候选药物ASC47的研究结果
智通财经网· 2025-06-09 00:14
Group 1 - Company announced that it will present early research data on oral small molecule GLP-1 receptor agonist ASC30 and fat-targeting weight loss candidate ASC47 at the 85th American Diabetes Association (ADA) Scientific Sessions in Chicago [1] - ASC30 is a clinical-stage small molecule GLP-1R agonist with unique properties allowing for both subcutaneous injection and oral tablet administration, protected by global compound patents until 2044 [1] - ASC47 is a self-developed fat-targeting, ultra-long-acting subcutaneous thyroid hormone receptor β (THRβ) selective small molecule agonist, showing dose-dependent high drug concentration in fat tissue [1] Group 2 - The ADA, established in 1940, is a leading non-profit organization focused on diabetes prevention and treatment, with its annual scientific sessions serving as a key industry benchmark [2] - The 85th ADA Scientific Sessions will take place from June 20 to 23 in Chicago, showcasing cutting-edge clinical practices and research directions in the diabetes field [2]
歌礼制药-B:ASC40痤疮适应症III期临床达到所有终点,疗效数据优秀-20250605
Soochow Securities· 2025-06-05 00:23
歌礼制药-B(01672.HK) ASC40痤疮适应症 III期临床达到所有终点, 疗效数据优秀 证券研究报告·海外公司点评·药品及生物科技(HS) 买入(维持) | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 56.69 | 1.28 | 0.00 | 40.00 | 100.00 | | 同比(%) | 4.81 | (97.74) | (100.00) | | 150.00 | | 归母净利润(百万元) | (144.72) | (300.94) | (454.44) | (469.72) | (445.21) | | 同比(%) | 54.04 | (107.95) | (51.01) | (3.36) | 5.22 | | EPS-最新摊薄(元/股) | (0.15) | (0.31) | (0.47) | (0.48) | (0.46) | | P/E(现价&最新摊薄) | (54.06) | (26.00) | ...
歌礼制药-B(01672):同类首创、每日一次口服FASN抑制剂地尼法司他(ASC40) 痤疮III期试验达到所有终点
智通财经网· 2025-06-03 23:15
智通财经APP讯,歌礼制药-B(01672)发布公告,同类首创(first-in-class)、每日一次口服小分子脂肪酸合成酶(FASN)抑制剂地尼法司他(ASC40)治疗中重度寻 常性痤疮的 III期临床试验(NCT06192264)达到所有主要、关键次要及次要终点。 主要、关键次要及次要终点可见表2。主要终点包括治疗成功百分比(治疗成功的定义为在第12周时,研究者总体评估(Investigator's Global Assessment,IGA) 评分较基线下降至少2分,且IGA分级为0分(光洁)或1分(几乎光洁))、总皮损计数相对基线百分比下降,以及炎性皮损计数相对基线百分比下降。第12周时, 地尼法司他治疗组治疗成功百分比为33.2%,而安慰剂组为14.6%,p <0.0001;地尼法司他治疗组总皮损计数相对基线百分比下降是57.4%,而安慰剂组为 35.4%,p <0.0001;以及,地尼法司他治疗组炎性皮损计数相对基线百分比下降是63.5%,而安慰剂组为43.2%,p <0.0001。第12周时,非炎性皮损计数相对 基线百分比下降(关键次要终点),地尼法司他治疗组为51.9%,而安慰剂组为28.9 ...
港股午评:恒生指数涨0.93%,恒生科技指数涨1.91%
news flash· 2025-05-12 04:01
港股午间收盘,恒生指数涨0.93%,恒生科技指数涨1.91%。苹果概念股领涨,舜宇光学科技涨超10%, 瑞声科技涨超9%。创新药板块领跌,歌礼制药-B跌超8%,百济神州跌超7%。 ...